Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
OptiNose
OptiNose
(OPTN)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Xhance
Fluticasone
2017-09-18
2024-2041
Chronic obstructive pulmonary disease
,
Asthma
,
Allergic rhinitis perennial
,
Bronchial spasm
,
Allergic conjunctivitis
,
Vasomotor rhinitis
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Fluticasone furoate
asthma
,
respiratory aspiration
,
nasal polyps
,
polyps
,
sinusitis
,
chronic disease
,
colorectal neoplasms
,
nasopharyngeal neoplasms
Fluticasone propionate
asthma
,
respiratory aspiration
,
migraine disorders
,
autistic disorder
,
autism spectrum disorder
,
pervasive child development disorders
,
nasal polyps
,
sinusitis
,
polyps
,
rhinosinusitis
,
chronic disease
,
colorectal neoplasms
,
nasopharyngeal neoplasms
Fluticasone
asthma
,
respiratory aspiration
,
migraine disorders
,
autistic disorder
,
autism spectrum disorder
,
pervasive child development disorders
,
nasal polyps
,
sinusitis
,
polyps
,
rhinosinusitis
,
chronic disease
,
colorectal neoplasms
,
nasopharyngeal neoplasms
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use